FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment - OncoDaily FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment / Aditya Bardia, Breast Cancer, cancer, Carlos H. Barrios, FDA, Gargi Patel, Giuseppe

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment
@fda.gov

oncodaily.com/insight/234405

#BreastCancer #Cancer #FDA #OncoDaily #Oncology #Medicine #DESTINY-Breast04Trial #Trastuzumab #Deruxtecan #Health

Morgan Stanley’s Top Oncology Catalysts for 2025 - OncoDaily Morgan Stanley’s Top Oncology Catalysts for 2025 / Antibody drug conjugates, AstraZeneca (AZN), BioNTech (BNTX), cancer, datopotamab deruxtecan, Gilead

Morgan Stanley’s Top Oncology Catalysts for 2025
@astrazeneca.bsky.social
@handle.invalid

oncodaily.com/insight/morg...

#AstraZeneca #AZN #BioNTech #BNTX #Cancer #Datopotamab #Deruxtecan #Gilead #GILD #Ivonescimab #Merck #Moderna #OncoDaily #Oncology #Pfizer #Regeneron #SMMT #Medicine #Health